Risk for Immune-Mediated Graft Dysfunction in Liver Transplant Recipients With Recurrent HCV Infection Treated With Pegylated Interferon

Levitsky, Josh; Fiel, M. Isabel; Norvell, John P.; Wang, Edward; Watt, Kymberly D.; Curry, Michael P.; Tewani, Sumeet K.; McCashland, Timothy M.; Hoteit, Maarouf; Shaked, Abraham; Saab, Samuel; Amanda, C.; Tien, Amy H.; Schiano, Thomas D.

doi:10.1053/j.gastro.2012.01.030

Cited by 100 publications

(73 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…3,12,13 Successful clearance of HCV after liver transplantation can reduce the risk of subsequent HCV-related complications such as progression to cirrhosis and graft loss. [13][14][15][16] The standard of care in the treatment of recurrent HCV genotype 1 infection after liver transplantation has been 48 weeks of peginterferon with ribavirin, though the response rates of 13 to 43% are generally lower than the rates of 40 to 52% among patients not undergoing transplantation, in part because of treatment-limiting toxic effects. 8,15,[17][18][19] In addition, interferon-based therapies can induce alloimmune graft injury, reducing patient and graft survival.…”

Section: Resultsmentioning

confidence: 99%

An Interferon-free Antiviral Regimen for HCV after Liver Transplantation

Mantry²,

et al. 2014

Self Cite

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

An Interferon-free Antiviral Regimen for HCV after Liver Transplantation

Mantry²,

et al. 2014

Self Cite

View full text Add to dashboard Cite

“…These low response rates were due, in part, to treatment-limiting side effects. Interferonbased treatments can also induce immunological damage in the liver graft, reducing its survival [7].…”

Section: Introductionmentioning

confidence: 99%

Paritaprevir-Ritonavir, Ombitasvir and Dasabuvir plus Ribavirin to Treat Hepatitis C Genotype 1 Infection after Liver Transplantation: A Single-Center Experience

Otero¹,

Vázquez²,

Suárez³

et al. 2017

Glob Surg

View full text Add to dashboard Cite

Hepatitis C virus (HCV) infection is a disease with a significant worldwide impact. In Europe and the United States, chronic hepatitis C is the most common cause of chronic hepatic disease and the main indication for liver transplantation. Recurrent hepatitis C infection is universal among transplant recipients who have detectable viremia at the time of transplantation. Hepatitis C treatment was revolutionized with the introduction of safe, powerful direct action antivirals (DAA), which allow the use of multidrug combinations that can selectively inhibit the targets required for viral replication. One of these regimens combined paritarpevir [NS3/4A protease inhibitor], ombitasvir [NS5A inhibitor] and dasabuvir [NS5B polymerase inhibitor], plus ribavirin and was found to be highly effective (SVR rates of 97% in genotype 1). We report the results of a real-world clinical practice study in a single clinical unit in 22 liver graft recipients, transplanted due to cirrhosis caused by genotype 1 HCV with post-transplantation viral recurrence, who received ombitsavir combined with paritaprevir-ritonavir plus dasabuvir and ribavirin.We found an SVR rate at 12 weeks post-treatment of 100% and a remarkably low rate of adverse events.Conclusion: oral ombitasvir combined with ritonavir-paritaprevir plus dasabuvir and ribavirin for 24 weeks is a highly effective treatment for eliminating HCV in liver transplant recipients with genotype 1 and scant fibrosis, producing few serious adverse effects.

show abstract

“…Besides their simplicity, suitable biocompatibility, nonimmunogenity, and protein adsorption resistance, these reactions often limit the controllability of network structures while they are not naturally degradable [5,6]. A recent study [7] showed that PEGylated parts made by the free-radical method cause specific clinical, biochemical, and histologic risk factors such as immune-mediated graft dysfunction. Furthermore, PEG-based hydrogels prepared by free-radical methods with low density of crosslinking sites often lack appropriate mechanical properties, which limit their application for bioactive cell delivery approach or soft tissue repair [8].…”

Section: Introductionmentioning

confidence: 99%

Injectable polyethylene glycol-laponite composite hydrogels as articular cartilage scaffolds with superior mechanical and rheological properties

Nojoomi

Tamjid

Simchi

et al. 2016

International Journal of Polymeric Materials and Polymeric Biom

View full text Add to dashboard Cite

TitleInjectable polyethylene glycol-laponite composite hydrogels as articular cartilage scaffolds with superior mechanical and rheological properties ABSTRACTIn this study, injectable PEG-based hydrogels containing Laponite particles with mechanical and structural properties close to the natural articular cartilage are introduced. The nanocomposites are fabricated by imide ring opening reactions utilizing synthesized copolymers containing PEG blocks and nanoclay through a two-step thermal poly-(amic acid) process. Butane diamine is used as nucleophilic reagent and hydrogels with interconnected pores with sizes in the range of 100-250 µm are prepared. Improved viscoelastic properties compared with the conventional PEG hydrogels are shown. Evaluation of cell viability utilizing human mesenchymal stem cells determines cytocompatibility of the nanocomposite hydrogels. GRAPHICAL ABSTRACT ARTICLE HISTORY

show abstract

Risk for Immune-Mediated Graft Dysfunction in Liver Transplant Recipients With Recurrent HCV Infection Treated With Pegylated Interferon

Cited by 100 publications

References 31 publications

An Interferon-free Antiviral Regimen for HCV after Liver Transplantation

An Interferon-free Antiviral Regimen for HCV after Liver Transplantation

Paritaprevir-Ritonavir, Ombitasvir and Dasabuvir plus Ribavirin to Treat Hepatitis C Genotype 1 Infection after Liver Transplantation: A Single-Center Experience

Injectable polyethylene glycol-laponite composite hydrogels as articular cartilage scaffolds with superior mechanical and rheological properties

Contact Info

Product

Resources

About